Navigation Links
BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
Date:1/28/2009

NOVATO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 18, at 5:00 p.m. ET (23:00 CET) to discuss fourth quarter and full year 2008 financial results.

    U.S. / Canada Dial-in Number:  866.700.6293
    International Dial-in Number:  617.213.8835
    Participant Code: 35749059
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 73992450

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

    Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

     Contacts:

     Investors                         Media
     Eugenia Shen                      Susan Berg
     BioMarin Pharmaceutical Inc.      BioMarin Pharmaceutical Inc.
     (415) 506-6570                    (415) 506-6594

'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Present at the Piper Jaffray Healthcare Conference
2. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
3. BioMarin to Present at the Credit Suisse Healthcare Conference
4. BioMarin Announces Third Quarter 2008 Financial Results
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
7. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
8. BioMarin to Present at the Citi Biotech Day
9. BioMarin Announces Roll-Out of National PKU Registry
10. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
11. BioMarin to Present at the Collins Stewart Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... Personal eye wash is a basic first aid ... at a time. So which eye do you rinse first if a dangerous substance enters ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its dirt ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
Breaking Biology Technology:
(Date:8/23/2017)... 2017  The general public,s help is being enlisted in what,s thought ... in and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the ... with the gut. The project's goal is to help advance scientific knowledge ... ...
(Date:7/20/2017)... WASHINGTON , July 20, 2017 Delta (NYSE: ... to board any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics ... Delta,s ... Delta Sky Club is now integrated into the boarding process to ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 ... a leader in dairy research, today announced a new ... help reduce the chances that the global milk supply ... this dairy project, Cornell University has become the newest ... Food Supply Chain, a food safety initiative that includes ...
Breaking Biology News(10 mins):